• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

    1.680 -0.020 (-1.18%)
    Streaming Delayed Price Updated: 11:44 AM EDT, Sep 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 9,973
    Open 1.710
    Bid (Size) 1.680 (3,600)
    Ask (Size) 1.840 (200)
    Prev. Close 1.700
    Today's Range 1.660 - 1.710
    52wk Range 1.170 - 2.710
    Shares Outstanding 78,986,490
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript ↗
    Lacutamab advances toward accelerated approval as ADC pipeline expands. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Innate Pharma Q2 Earnings Call Highlights ↗
    Innate Pharma (NASDAQ:IPHA) said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and... 
    Via MarketBeat
    Topics Earnings

    Performance

    YTD
    -7.7%
    -7.7%
    1 Month
    -24.3%
    -24.3%
    3 Month
    -6.7%
    -6.7%
    6 Month
    +33.3%
    +33.3%
    1 Year
    -7.7%
    -7.7%

    More News

    Read More
    News headline image
    Innate Pharma Reports First Half 2026 Business Update and Financial Results
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma Secures €30M, Extends Cash Runway Into 2028 ↗
    Via MarketBeat
    News headline image
    Innate Pharma Announces Conference Call and Webcast
    From Innate Pharma SA
    Via Business Wire
    Unusual volume stocks are being observed in Wednesday's session. ↗
    Via Chartmill
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    News headline image
    Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Outcome of Innate Pharma’s 2026 Annual General Meeting
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to participate in the Jefferies Global Healthcare Conference
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to Participate in the D. Boral Capital Global Conference
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
    From Innate Pharma SA
    Via Business Wire
    News headline image
    Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
    From Innate Pharma SA
    Via Business Wire

    Frequently Asked Questions

    Is Innate Pharma S.A. - American Depositary Shares publicly traded?
    Yes, Innate Pharma S.A. - American Depositary Shares is publicly traded.
    What exchange does Innate Pharma S.A. - American Depositary Shares trade on?
    Innate Pharma S.A. - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Innate Pharma S.A. - American Depositary Shares?
    The ticker symbol for Innate Pharma S.A. - American Depositary Shares is IPHA on the Nasdaq Stock Market
    What is the current price of Innate Pharma S.A. - American Depositary Shares?
    The current price of Innate Pharma S.A. - American Depositary Shares is 1.680
    When was Innate Pharma S.A. - American Depositary Shares last traded?
    The last trade of Innate Pharma S.A. - American Depositary Shares was at 09/28/26 11:44 AM ET
    What is the market capitalization of Innate Pharma S.A. - American Depositary Shares?
    The market capitalization of Innate Pharma S.A. - American Depositary Shares is 132.70M
    How many shares of Innate Pharma S.A. - American Depositary Shares are outstanding?
    Innate Pharma S.A. - American Depositary Shares has 133M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.